NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

2022 projections:

Easy:

. No approval by any RA.
. Revenue from Specials will be nowhere close to the numbers likes $50-$100M many post. May be above my best guess of $2M, but not much.
. They will raise cash somehow.
. A vote for more shares (or some equivalent)
. No data from the combo trial
. No merger / buyouts with a BP

Not as certain but likely:

. They find a way to monetize Sawston
. No true data release (full results in a top tier journal)
. No statement they have submitted any BLA/MAA
. No clear statement about what the trial endpoints are
. ASCO bype will shift from the "big booth" to "tote bags".

Flame on, we can score it up in a year.